Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics' stock has been impacted by several key events in the past six months. The company announced and closed a public offering of common stock, raising approximately $173 million in gross proceeds, extending its cash runway into 2030. Following the public offering announcement, Trevi's shares experienced a surge, reaching an all-time high, but also experienced some volatility after its Q1 2026 earnings call. The company reported its Fourth Quarter and Year End 2025 financial results in March 2026 and its First Quarter 2026 financial results in May 2026, with the Q1 report indicating a net loss of $13.2 million. Trevi Therapeutics completed an End-of-Phase 2 meeting with the FDA and plans to initiate Phase 3 trials for IPF-related chronic cough in 2026, along with Phase 2b trials for non-IPF ILD-related chronic cough and RCC. Trevi Therapeutics has participated in various healthcare conferences and investor events.

Trevi Therapeutics, Inc. does not currently have commercialized products or services subject to traditional consumer demand seasonality. The demand for Haduvio is driven by its progression through clinical trials and the regulatory approval process. Commercial market demand for Haduvio would only become relevant upon successful FDA approval and subsequent launch, projected for late 2029 for IPF-related chronic cough.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio (oral nalbuphine extended-release) for neurologically mediated conditions. The company operates in the Healthcare sector, specifically in Biotechnology and Pharmaceuticals, with a focus on drug discovery. Their primary product candidate, Haduvio, is being developed for chronic cough in patients with IPF, non-IPF ILD, and RCC. Trevi Therapeutics holds a license agreement with Keenova Therapeutics plc for products incorporating nalbuphine hydrochloride.

Trevi Therapeutics, Inc. is headquartered in New Haven, Connecticut, United States.

Trevi Therapeutics' brand reputation is primarily linked to the progress and outcomes of its clinical trials for Haduvio and its financial stability. The company generally maintains a positive reputation within the investment community, with analysts providing a consensus "Buy" or "Strong Buy" rating. News sentiment has been largely neutral to positive, focusing on clinical advancements, successful capital raises, and an extended cash runway.

Trevi Therapeutics, Inc. has significant institutional ownership, with 194 institutional owners and shareholders holding approximately 91.78% of the stock. Major institutional owners include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., and BlackRock, Inc. New Enterprise Associates, Inc. is the largest shareholder with 9.5% of shares outstanding. Individual insider ownership is reported to be around 121.40% by one source, and under 1% by another, with Forest Baskett being the largest individual shareholder. The general public holds about 22% ownership.